India releases biosimilar manufacturing guide; Frazier wraps up packaging deal;

> India used the BIO 2012 conference to release new "similar biologics" guidelines that will require manufacturers of biosimilars prove similarity within four years of post-market safety data to either a drug licensed in India or one approved elsewhere. Story

> Catalent Pharma Solutions is partnering with formulation specialists Bend Research to offer integrated solutions for the development and manufacture of specialized multiparticulate oral controlled-release products. News

> Pluristem Therapeutics, a developer of placenta-based stem-cell therapies, is building a manufacturing facility near its headquarters in Haifa, Israel, even before it has gotten its therapy approved. Story

> Food Standards Australia New Zealand is alerting the public against taking sports food supplements containing 1,3-dimethylamylamine (DMAA) because of its links to high blood pressure and other adverse health effects. Item

> Frazier Healthcare has completed its acquisition of Catalent Pharma Solutions' U.S. commercial pharmaceutical packaging operations and will run as Packaging Coordinators, Inc., which is what it was previously named. Report

> Healthpoint Biotherapeutics says it will invest about $60 million to add 25,000 square feet of manufacturing infrastructure, as well as lab and clean room space in Fort Worth, TX, for production of its cell-based products. Announcement

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.